首頁 > 市場調查報告書 > 製藥

循環系統

市場調查報告書

商品編碼

1668062

靜脈血栓栓塞症預防市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、最終用途、地區和競爭細分，2020-2030 年預測

Venous Thromboembolism Prophylaxis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End Use, By Region and Competition, 2020-2030F

出版日期: 2025年02月28日 | 出版商:

TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球靜脈血栓栓塞症預防市場價值為 68.2 億美元，預計到 2030 年將達到 94.6 億美元，複合年成長率為 5.58%。預計到 2030 年將達到 94.6 億美元，複合年成長率為 5.58%。人們對未經治療的 VTE 相關併發症的認知不斷提高，導致人們廣泛採用預防措施，包括抗凝血劑等藥物干預和壓迫裝置等機械方法。醫療保健基礎設施的擴展和診斷技術的進步使得早期發現和治療高風險患者成為可能。醫院和門診護理機構對病人安全協議的日益重視進一步推動了 VTE 預防的採用。人工智慧（AI）和預測分析在識別高風險個體方面的整合正在改善治療結果並最佳化資源分配。

市場概況
預測期	2026-2030
2024 年市場規模	68.2 億美元
2030 年市場規模	94.6 億美元
2025-2030 年複合年成長率	5.58%
成長最快的領域	門診護理中心
最大的市場	北美洲

癌症、心血管疾病和肥胖等慢性疾病的發生率不斷上升，導致對有效 VTE 預防治療的需求不斷增加。直介面服抗凝血劑 (DOAC) 作為傳統抗凝血劑的更安全、更方便的替代品，越來越受到人們的青睞。向門診護理和微創手術的轉變加速了對醫院以外預防措施的需求。間歇性氣動壓縮 (IPC) 系統和漸進式壓力襪等機械預防設備的技術進步正在提高患者的依從性和治療效果。促進血栓預防的醫療政策和報銷計劃正在加強市場成長。預計生物製劑和下一代抗凝血劑研究的不斷加強將引入創新的治療方案，降低出血風險，同時確保有效預防血栓。老年人口的不斷成長，使人們更容易感染靜脈血栓栓塞症 (VTE)，這為預防性治療帶來了巨大的成長潛力。

發展中地區對 VTE 預防的認知和可近性有限仍然是市場擴張的重大障礙。新型抗凝血療法和機械裝置的高成本限制了人們的負擔能力，尤其是對於低收入者而言。由於擔心出血風險和抗凝血劑的潛在副作用而導致患者猶豫，從而影響採用率。新藥和新設備的嚴格法規核准流程導致產品進入市場的延遲，從而限制了先進預防治療方案的可用性。某些醫療機構未遵守 VTE 預防指南，導致預防策略實施不一致。管理患有多種合併症的患者的 VTE 風險的複雜性給醫療保健提供者帶來了額外的挑戰。透過有針對性的宣傳計劃、具成本效益的治療方案和簡化的監管途徑解決這些障礙對於全球靜脈血栓栓塞症預防市場持續成長至關重要。

主要市場促進因素

人口老化

主要市場挑戰

預防費用

主要市場趨勢

數位健康整合

Global Venous Thromboembolism Prophylaxis Market was valued at USD 6.82 Billion in 2024 and is expected to reach USD 9.46 Billion in the forecast period with a CAGR of 5.58% through 2030. The Global Venous Thromboembolism (VTE) Prophylaxis Market is witnessing steady growth due to the rising incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE), which pose significant health risks, particularly among hospitalized and post-surgical patients. Increased awareness of the complications associated with untreated VTE has led to the widespread adoption of prophylactic measures, including pharmacological interventions such as anticoagulants and mechanical methods like compression devices. The expansion of healthcare infrastructure and advancements in diagnostic technologies are enabling early detection and treatment of at-risk patients. Growing emphasis on patient safety protocols in hospitals and ambulatory care settings is further driving the adoption of VTE prophylaxis. The integration of artificial intelligence (AI) and predictive analytics in identifying high-risk individuals is improving treatment outcomes and optimizing resource allocation.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.82 Billion
Market Size 2030	USD 9.46 Billion
CAGR 2025-2030	5.58%
Fastest Growing Segment	Ambulatory care Centers
Largest Market	North America

Increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and obesity is contributing to the rising demand for effective VTE prophylaxis. The adoption of direct oral anticoagulants (DOACs) as a safer and more convenient alternative to traditional anticoagulants is gaining traction. The shift towards outpatient care and minimally invasive surgeries is accelerating the need for preventive measures beyond hospital settings. Technological advancements in mechanical prophylaxis devices, such as intermittent pneumatic compression (IPC) systems and graduated compression stockings, are improving patient compliance and outcomes. Healthcare policies and reimbursement programs promoting thromboprophylaxis are strengthening market growth. Increasing research in biologics and next-generation anticoagulants is expected to introduce innovative treatment options, reducing bleeding risks while ensuring effective clot prevention. The rising geriatric population, which is more susceptible to VTE, presents significant growth potential for prophylactic therapies.

Limited awareness and accessibility of VTE prophylaxis in developing regions remain significant barriers to market expansion. High costs associated with novel anticoagulant therapies and mechanical devices restrict affordability, particularly in low-income populations. Patient hesitation due to concerns about bleeding risks and potential side effects of anticoagulants affects adoption rates. Stringent regulatory approval processes for new drugs and devices lead to delays in market entry, limiting the availability of advanced prophylactic options. The lack of adherence to VTE prevention guidelines in certain healthcare facilities results in inconsistent implementation of prophylaxis strategies. The complexity of managing VTE risks in patients with multiple comorbidities poses additional challenges for healthcare providers. Addressing these barriers through targeted awareness programs, cost-effective treatment solutions, and streamlined regulatory pathways will be crucial for the sustained growth of the Global Venous Thromboembolism Prophylaxis Market.

Key Market Drivers

Aging Population

The aging population is a significant driving force behind the growth of the Global Venous Thromboembolism (VTE) Prophylaxis Market. As the global population continues to age, there is a marked increase in the incidence of VTE-related health issues, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Elderly individuals are particularly vulnerable to VTE due to factors like reduced mobility, comorbidities, and alterations in blood composition. This demographic shift has led to a heightened demand for effective VTE prophylactic measures.

One primary reason for this increased demand is the higher prevalence of surgical procedures among older individuals. Surgical interventions, especially orthopedic and major surgeries, are known risk factors for VTE. The elderly population frequently undergoes joint replacements, cardiac surgeries, and other medical interventions, increasing their risk. Healthcare providers are acutely aware of this risk and are increasingly implementing prophylactic strategies, such as anticoagulant medications and mechanical devices, to minimize the likelihood of VTE in their elderly patients.

Furthermore, the elderly population's vulnerability to VTE is exacerbated by decreased mobility and lifestyle changes. Reduced physical activity and prolonged periods of immobility, such as extended bed rest or long flights, can significantly elevate the risk of blood clots. As the aging population seeks to maintain their mobility and quality of life, the demand for VTE prophylaxis becomes even more critical.

Pharmaceutical companies have responded to this growing need by developing anticoagulant medications with improved safety profiles and dosing regimens suitable for older patients. Additionally, medical device manufacturers have introduced more comfortable and efficient mechanical prophylaxis devices, ensuring that VTE prevention options are well-suited for elderly individuals.

Key Market Challenges

Cost of Prophylaxis

The price tag associated with VTE prevention, especially in the case of anticoagulant medications and mechanical devices, can be overwhelming for both healthcare systems and patients. This becomes particularly evident in regions with limited healthcare budgets or in countries where out-of-pocket expenses for medical treatments are high. Such expenses can deter individuals from seeking prophylactic measures, even when they are at risk of developing VTE.

Anticoagulant medications, while effective, often come with a high cost, especially the newer, more advanced drugs with better safety profiles and fewer side effects. For many patients, these medications need to be taken long-term, leading to escalating costs over time. Additionally, mechanical prophylaxis devices, such as intermittent pneumatic compression (IPC) pumps or advanced compression stockings, can also be pricey. While these devices are vital for patients who cannot take anticoagulants due to contraindications, their costs can be a significant barrier to widespread adoption.

Furthermore, the financial implications of VTE prophylaxis are not limited to the direct cost of medications and devices. Monitoring patients, especially those on anticoagulant medications, requires regular blood tests and follow-ups, incurring additional expenses. For many patients, especially those without comprehensive insurance coverage, these cumulative costs can be daunting.

Key Market Trends

Digital Health Integration

Digital health integration is emerging as a pivotal driver behind the growth of the Global Venous Thromboembolism (VTE) Prophylaxis Market. VTE, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), affects up to 900,000 Americans annually, with an estimated 60,000 to 100,000 deaths each year. The integration of digital health technologies is revolutionizing VTE prophylaxis management, leading to more effective prevention and improved patient outcomes.

Electronic health records (EHRs) serve as a cornerstone in this integration, enabling healthcare providers to swiftly access patient histories, risk factors, and medication profiles. This real-time data access facilitates timely risk assessments, ensuring high-risk patients receive appropriate prophylactic measures. Studies have shown that implementing EHRs can reduce medication errors by 54% and adverse drug reactions by 36%, thereby enhancing patient safety.

Remote patient monitoring systems also play a vital role in enhancing VTE prevention. These systems allow continuous monitoring of patients post-discharge, tracking activity levels, vital signs, and medication adherence. Such surveillance is crucial, as more than one-third of VTE cases are associated with recent hospitalizations, with many events occurring after discharge. By detecting early warning signs of VTE development, healthcare teams can intervene promptly, significantly reducing incidence rates and improving patient safety.

Telemedicine platforms further contribute to VTE prophylaxis by facilitating virtual consultations, enabling healthcare providers to assess risk factors and guide prophylactic measures remotely. This approach is particularly beneficial given that as many as 70% of healthcare-associated VTE cases are preventable through measures such as anticoagulant medications or compression stockings. Remote consultations enhance patient education and engagement, promoting adherence to preventive strategies.

Key Market Players

Arjo
Encompass Group
Argon Medical Devices
MEGO AFEK
Zenith Technical Innovations
Cook Medical
Bio Compression Systems
ThermoTek USA
Boston Scientific Corporation
Cardinal Health (Medtronic)

Report Scope:

In this report, the Global Venous Thromboembolism Prophylaxis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Venous Thromboembolism Prophylaxis Market, By Type:

Lower Extremity
Upper Extremity

Venous Thromboembolism Prophylaxis Market, By End Use:

Hospitals & Clinics
Ambulatory care Centers
Others

Venous Thromboembolism Prophylaxis Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Venous Thromboembolism Prophylaxis Market.

Available Customizations:

Global Venous Thromboembolism Prophylaxis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Global Venous Thromboembolism Prophylaxis Market Outlook

4.1. Market Size & Forecast
- 4.1.1. By Value
4.2. Market Share & Forecast
- 4.2.1. By Type (Lower Extremity, Upper Extremity)
- 4.2.2. By End Use (Hospitals & Clinics, Ambulatory care Centers, Others)
- 4.2.3. By Company (2024)
4.3. Market Map
- 4.3.1. By Type
- 4.3.2. By End Use
- 4.3.3. By Region

5. Asia Pacific Venous Thromboembolism Prophylaxis Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type
- 5.2.2. By End Use
- 5.2.3. By Country
5.3. Asia Pacific: Country Analysis
- 5.3.1. China Venous Thromboembolism Prophylaxis Market Outlook
  - 5.3.1.1. Market Size & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share & Forecast
    - 5.3.1.2.1. By Type
    - 5.3.1.2.2. By End Use
- 5.3.2. India Venous Thromboembolism Prophylaxis Market Outlook
  - 5.3.2.1. Market Size & Forecast
    - 5.3.2.1.1. By Value
  - 5.3.2.2. Market Share & Forecast
    - 5.3.2.2.1. By Type
    - 5.3.2.2.2. By End Use
- 5.3.3. Australia Venous Thromboembolism Prophylaxis Market Outlook
  - 5.3.3.1. Market Size & Forecast
    - 5.3.3.1.1. By Value
  - 5.3.3.2. Market Share & Forecast
    - 5.3.3.2.1. By Type
    - 5.3.3.2.2. By End Use
- 5.3.4. Japan Venous Thromboembolism Prophylaxis Market Outlook
  - 5.3.4.1. Market Size & Forecast
    - 5.3.4.1.1. By Value
  - 5.3.4.2. Market Share & Forecast
    - 5.3.4.2.1. By Type
    - 5.3.4.2.2. By End Use
- 5.3.5. South Korea Venous Thromboembolism Prophylaxis Market Outlook
  - 5.3.5.1. Market Size & Forecast
    - 5.3.5.1.1. By Value
  - 5.3.5.2. Market Share & Forecast
    - 5.3.5.2.1. By Type
    - 5.3.5.2.2. By End Use

6. Europe Venous Thromboembolism Prophylaxis Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By End Use
- 6.2.3. By Country
6.3. Europe: Country Analysis
- 6.3.1. France Venous Thromboembolism Prophylaxis Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By End Use
- 6.3.2. Germany Venous Thromboembolism Prophylaxis Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By End Use
- 6.3.3. Spain Venous Thromboembolism Prophylaxis Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By End Use
- 6.3.4. Italy Venous Thromboembolism Prophylaxis Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Type
    - 6.3.4.2.2. By End Use
- 6.3.5. United Kingdom Venous Thromboembolism Prophylaxis Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Type
    - 6.3.5.2.2. By End Use

7. North America Venous Thromboembolism Prophylaxis Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By End Use
- 7.2.3. By Country
7.3. North America: Country Analysis
- 7.3.1. United States Venous Thromboembolism Prophylaxis Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By End Use
- 7.3.2. Mexico Venous Thromboembolism Prophylaxis Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By End Use
- 7.3.3. Canada Venous Thromboembolism Prophylaxis Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By End Use

8. South America Venous Thromboembolism Prophylaxis Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By End Use
- 8.2.3. By Country
8.3. South America: Country Analysis
- 8.3.1. Brazil Venous Thromboembolism Prophylaxis Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By End Use
- 8.3.2. Argentina Venous Thromboembolism Prophylaxis Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By End Use
- 8.3.3. Colombia Venous Thromboembolism Prophylaxis Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By End Use

9. Middle East and Africa Venous Thromboembolism Prophylaxis Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By End Use
- 9.2.3. By Country
9.3. MEA: Country Analysis
- 9.3.1. South Africa Venous Thromboembolism Prophylaxis Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By End Use
- 9.3.2. Saudi Arabia Venous Thromboembolism Prophylaxis Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By End Use
- 9.3.3. UAE Venous Thromboembolism Prophylaxis Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By End Use

10. Market Dynamics

10.1. Drivers
10.2. Challenges

11. Market Trends & Developments

11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions

12. Global Venous Thromboembolism Prophylaxis Market: SWOT Analysis

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product

14. Competitive Landscape

14.1. Arjo
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Current Capacity Analysis
- 14.1.5. Financials (In case of listed)
- 14.1.6. Recent Developments
- 14.1.7. SWOT Analysis
14.2. Encompass Group
14.3. Argon Medical Devices
14.4. MEGO AFEK
14.5. Zenith Technical Innovations
14.6. Cook Medical
14.7. Bio Compression Systems
14.8. ThermoTek USA
14.9. Boston Scientific Corporation
14.10.Cardinal Health (Medtronic)